Top

Published in:

01-05-2014 | Research Article

RETRACTED ARTICLE: Polyamidoamine dendrimer liposome-mediated survivin antisense oligonucleotide inhibits hepatic cancer cell proliferation by inducing apoptosis

Authors: Shuai Han, Zhai Cai, Liang Peng, Zhou Li, Hua-Bin Zhou, Xiu-Qin Li, Su-Zhen Fang, Zong-Hai Huang, Da-Xiang Cui

Published in: Tumor Biology | Issue 5/2014

Abstract

Polyamidoamine dendrimer (PAMAM) is a new nanometer material, which can transfer the target genes to cells with high efficiency and lower toxicity. This study aims to evaluate antitumor effects of survivin antisense oligonucleotide (survivin-asODN) (carried by polyamidoamine dendrimer liposome) on hepatic cancer in nude mice. Hepatic cancer model was established by injecting SMMC-7721 cells subcutaneously into flanks of nude mice. Polyamidoamine dendrimer and liposome were mixed with survivin-asODN, respectively. The shape and size of complex were observed by transmission electron microscope, and zeta potential was measured by an analytical tool. Encapsulation efficiency and DNA loading level were determined by an ultraviolet spectrophotometer in centrifuging method. Expression of survivin in transplant tumor was measured by Western blotting. No significant difference appeared for diameter and envelopment ratio between PAMAM liposome-survivin-asODN and PAMAM-survivin-asODN (P > 0.05). Both zeta potential and transfection efficiency in PAMAM liposome-survivin-asODN were higher than that in PAMAM-survivin-asODN complex (P < 0.05). Expression of survivin protein and weight of tumors in transplanted tumors in PAMAM liposome-survivin-asODN group was less than that in PAMAM-survivin-asODN group (P < 0.05). Cell apoptosis rate in PAMAM liposome-survivin-asODN group was higher than that of PAMAM-survivin-asODN group (P < 0.05). In conclusion, polyamidoamine dendrimer liposome can deliver survivin-asODN into hepatic transplanted tumor cells effectively. Ployamidoamine dendrimer liposome-mediated survivin-asODN can inhibit hepatic cell proliferation by inducing apoptosis.

Yuan L, Zhao H, Zhang L, Liu X. The efficacy of combination therapy using adeno-associated virus-mediated co-expression of apoptin and interleukin-24 on hepatocellular carcinoma. Tumor Biol. 2013;34(5):3027–2034.CrossRef

Pan B, Cui D, Sheng Y, Ozkan C, Gao F, He R, et al. Dendrimer-modified magnetic nanoparticles enhance efficiency of gene delivery system. Cancer Res. 2007;67(17):8156–63.CrossRefPubMed

Bhattacharyya S, Kudgus RA, Bhattacharya R, Mukherjee P. Inorganic nanoparticles in cancer therapy. Pharm Res. 2011;28(2):237–59.CrossRefPubMed

Li Z, Fang SZ, Han S, Cui DX, Li Q, Cai Z, et al. Survivin antisense oligonucleotide mediated by polyamidoaminedendrimer liposome induces apoptosis of hepatic cancer cells. Chin J Cancer Biother. 2012;19(4):409–13.

Li XQ, Pei DS, Qian GW, Yin XX, Cheng Q, Li LT, et al. The effect of methylated oligonucleotide targeting Ki-67 gene in human 786-O renal carcinoma cells. Tumor Biol. 2011;32(5):863–72.CrossRef

Millan A, Huerta S. Apoptosis-inducing factor and colon cancer. J Surg Res. 2009;151(1):163–70.CrossRefPubMed

Sun NF, Tian AL, Liu ZA, Hu SY, Hu AB. Antiapoptotic gene BAG-1 vector structure of RNA interference and endogenous targeted screening in colon cancer cell lines. Tumor Biol. 2013. doi:10.1007/s13277-013-1140-1.

Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 1997;3(8):917–21.CrossRefPubMed

Zhang Y, Zhang Y, Chen J, Zhang B, Pan Y, Ren L, et al. Polybutylcyanoacrylate nanoparticles as novel vectors in cancer gene therapy. Nanomedicine. 2007;3(2):144–53.CrossRefPubMed

10.

Ao L, Gao F, Pan B, He R, Cui D. Fluoroimmunoassay for antigen based on fluorescence quenching signal of gold nanoparticles. Anal Chem. 2006;78(4):1104–6.CrossRefPubMed

11.

Li F, Altieri DC. Transcriptional analysis of human survivin gene expression. Biochem J. 1999;344(2):305–11.PubMedPubMedCentral

12.

Reed JC. Dysregulation of apoptosis in cancer. J Clin Oncol. 1999;17(9):2941–53.CrossRefPubMed

13.

Cui D, Huang P, Zhang C, Ozkan CS, Pan B, Xu P. Dendrimer-modified gold nanorods as efficient controlled gene delivery system under near-infrared light irradiation. J Control Release. 2011;152 Suppl 1:e137–9.CrossRefPubMed

14.

Svenson S. Dendrimers as versatile platform in drug delivery applications. Eur J Pharm Biopharm. 2009;71(3):445–62.CrossRefPubMed

15.

Hector S, Rehm M, Schmid J, Kehoe J, McCawley N, Dicker P, et al. Clinical application of a systems model of apoptosis execution for the prediction of colorectal cancer therapy responses and personalisation of therapy. Gut. 2012;61(5):725–33.CrossRefPubMed

16.

Wong PE, Tetley L, Dufes C, Chooi KW, Bolton K, Schatzlein AG, et al. Polyamine aza-cyclic compounds demonstrate anti-proliferative activity in vitro but fail to control tumour growth in vivo. J Pharm Sci. 2010;99(11):4642–57.CrossRefPubMed

17.

Prabha S, Zhou WZ, Panyam J, Labhaseltwar V. Size-dependency of nanoparticle-mediated gene transfection: studies with fractionated nanoparticles. Int J Pharm. 2002;244(1–2):105–15.CrossRefPubMed

18.

Navarro G, Tros DIC. Activated and non-activated PAMAM dendrimers for gene delivery in vitro and in vivo. Nanomedicine. 2009;5(3):287–97.CrossRefPubMed

19.

Huang M, Khor E, Lim LY. Uptake and cytotoxicity of chitosan molecules and nanoparticles: effects of molecular weight and degree of deacetylation. Pharm Res. 2004;21(2):344–53.CrossRefPubMed

20.

Wang C, Wang W, Wang J, Zhan H, Jiang L, Yan R, et al. Apoptin induces apoptosis in nude mice allograft model of human bladder cancer by altering multiple bladder tumor associated gene expression profiles. Tumor Biol. 2013;34(3):1667–78.CrossRef

21.

Surendiran A, Sandhiya S, Pradhan SC, Adithan C. Novel applications of nanotechnology in medicine. Indian J Med Res. 2009;130(6):689–701.PubMed

Title: RETRACTED ARTICLE: Polyamidoamine dendrimer liposome-mediated survivin antisense oligonucleotide inhibits hepatic cancer cell proliferation by inducing apoptosis
Authors: Shuai Han
Zhai Cai
Liang Peng
Zhou Li
Hua-Bin Zhou
Xiu-Qin Li
Su-Zhen Fang
Zong-Hai Huang
Da-Xiang Cui
Publication date: 01-05-2014
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 5/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-014-1661-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2014

Methylation of miR-124a-1, miR-124a-2, and miR-124a-3 genes correlates with aggressive and advanced breast cancer disease

Transforming growth factor beta1 (TGFβ1) polymorphisms and breast cancer risk

INPP4B overexpression enhances the antitumor efficacy of PARP inhibitor AG014699 in MDA-MB-231 triple-negative breast cancer cells

Sprouty4 interferes with cell proliferation and migration of breast cancer-derived cell lines

Efficacy of acetylsalicylic acid (aspirin) in skin B16-F0 melanoma tumor-bearing C57BL/6 mice

Diagnostic value of alpha-l-fucosidase for hepatocellular carcinoma: a meta-analysis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer